The orthodontic treatment of patients on bisphosphonates is becoming an increasing aspect of contemporary practice. This article will draw attention to the chemical structure and effects of these drugs on bone and will provide the latest recommendations to avoid potential sequelae.
GattiD, AdamiS.New bisphosphonates in the treatment of bone diseases. Drugs Aging1999; 15: 285–96.
6.
DrakeMT, ClarkeBL, KhoslaS.Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc2008; 83: 1032–45.
7.
Biphosphonates fact file. September BDA2008 (1).
8.
PlasmansCM, JapPH, KuijpersW, SlooffTJ. Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int1980; 32: 247–66.
9.
KimTW, YoshidaY, YokoyaK, SasakiT.An ultrastructural study of the effects of bisphosphonate administration on osteoclastic bone resorption during relapse of experimentally moved rat molar. Am J Orthod Dentofacial Orthop1999; 115: 645–53.
10.
MiglioratiCA, CasigliaJ, EpsteinJ.Managing the care of patients with bisphosphonate associated osteonecrosis. J Am Dent Assoc2005; 136: 1658–68.
11.
BoivinG, MeunierP.Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact2002; 2: 538–43.
12.
ChavassieuxPM, ArlotME, RedaC, WeiL, YatesAJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest1997; 100: 1475–80.
13.
BrumsenC, amdy NAHamdyNA, PapapoulosSE. Long-term effects of bisphosphonates on the growing skeleton: Studies of young patients with severe osteoporosis. Med1997; 76: 266–83.
14.
MeunierPJ, ArlotM, ChavassieuxP, YatesAJ. The effects of alendronate on bone turnover and bone quality. Int J Clin Pract Suppl1999; 101: 14–17.
15.
LinJH. Bisphosphonates: a review of their pharmacokinetic properties. Bone1996; 18: 75–85.
16.
MarxRE. Oral and Intravenous bisphosphonates-induced osteonecrosis of the jaws: history, etiology, prevention and treatment. Hanover Park, IL: Quitessence, 2007..
17.
RizzoloD, SedrakM.Managing the adverse effects of bisphosphonate therapy on the jaw. JAAPA2009; 22: 48–52.
18.
RuggieroSL, DodsonTB, AssaelLA. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg2009; 67: 2–12.
19.
RuggieroS.Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann NY Acad Sci2010; 1218: 38–46.
20.
Osteoporosis medications and your dental health pamphlet #W418, American Dental Association/National Osteoporosis Foundation, 2008.
21.
BamiasA, KastritisE, BamiaC.Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol2005; 23: 1567–75.
22.
DurieBG, KatzM, CrowleyJ.Osteonecrosis of the jaws and bisphosphonates. N Engl J Med2005; 353: 99–102.
PazianasM, MillerP, BlumentalsWA, BernalM, KothawalaP.A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther2007; 29: 1548–58.
26.
ScolettaM, ArduinoPG, PolR.Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. J Oral Maxillofac Surg2011; 2: 456–62.
27.
WattsNB, DiabDL. Long-term use of bisphosphonates in osteoporosis. J Clin Endoncrinol Metab2010; 95: 1555–65.
28.
WysowskiDK. Reports of esophageal cancer with oral bisphosphonate use. N Engl Med2009; 360: 1791 (Letter).
29.
SirisES, OsterMW, BilezikianJP. More on reports of esophagal cncer with oral bisphosphonate use. N Engl J Med2009; 360: 1791 (Letter).
30.
StackR, TarrK.Drug-induced optic neuritis and uveitis secondary to bisphosphonates. NZ Med J2006; 119(1230): U1888.
31.
MillerPD, RouxC, BoonenS, BartonIP, DunlapLE, BurgioDE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a polled analysis of nine clinical trials. J Bone Miner Res2005; 20: 2105–15.
32.
BlackDM, DelmasPD, EastellR.Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med2007; 356: 1809–22.
CaplanL, PittmanCB, ZeringueAL. An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy. Mayo Clin Proc2010; 85: 341–48.
35.
PapapoulosSE, CremersSC. Prolonged bisphosphonate release after treatment in children. N Engl J Med2007; 365: 1075–76.
36.
KennelKA, DrakeMT. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc2009; 84: 632–38.
37.
RosenHN, MosesAC, GarberJ.Serum CTX. A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphophonate therapy. Calcif Tissue Int2000; 66: 100–03.
38.
JuHS, LeungS, BrownB.Comparison of analytical erformance and biological variability of three bone resorption assays. Clin Chem1997; 43: 1570–76.
39.
MarxRE, CIlloJEJr, UlloaJJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg2007; 12: 2397–410.
40.
RochaML, MalacaraJM, Sanchez-MarinFJ, Vazquez de la TorreCJ, FajardoME. Effects of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol2004; 75: 1579–85.
41.
ArrainY, MasudT.Recent recommendations on bisphophonate-associated osteonecrosis of the jaw. Dental Update2008; 35: 238–42.
42.
LaneN, ArmitageGC, LoomerP.Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol2005; 76: 1113–22.
43.
American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral biphosphonate therapy. J Am Dent Assoc2006; 137: 1144–50.
44.
MasellaRS, MeisterM.Current concepts in the biology of orthodontic tooth movement. Am J Orthod Dentofacial Orthop2006; 129: 458–68.
45.
KimTW, YoshidaY, YokoyaK, SasakiT.An ultrastructural study of the effects of bisphosphonate administration on osteoclastic bone resorption during relapse of experimentally moved rat molar. Am J Orthod Dentofac Orthop1999; 115: 645–53.
46.
ChoiJ, BaekSH, LeeJI, ChangYI. Effects of clodronate on early alveolar bone remodeling and root resorption related to orthodontic forces: a histomorphometric analysis. Am J Orthod Dentofac Orthop2010; 5: 548–49.
47.
PampuAA, DolanmazD, TüzHH, KarabacakogluA.Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis. J Oral Maxillofac Surg2006; 64: 1232–36.
48.
KimuraM, MiyazawaK, TabuchiM.Bisphosphonate treatment increases the size of the mandibular condyle and normalizes growth of the mandibular ramus in osteoprotegerin-deficient mice. Calcif Tissue Int2008; 2: 137–47.
49.
ZavrasAI. The impact of bisphosphonates on oral health: lessons from the past and opportunities for the future. Ann NY Acad Sci2011; 1218: 55–61.
50.
Iglesias-LenaresA, Yáñez-VicoRM, Solano-ReinaE, Torres-LagaresD, González MolesMA. Influence of bisphosphonates in orthodontic therapy: systematic review. J Dent2010; 8: 603–11.
51.
AdachiH, IgarashiK, MitaniH, ShinodaH.Effects of topical administration of a bisphosphonate (Risedromate) on orthodontic tooth movements in rats. J Dent Res1994; 73: 1478–86.
52.
NaseJB, SuzukiJB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc2006; 137: 1115–19.
